A new machine-learning analysis of a large group of migraine patients has identified subgroups that share both clinical and therapeutic response traits.
Dr Nathaniel Schuster from UC San Diego and colleagues tested a cannabis product with 6% THC based on prior studies showing efficacy of that concentration for other pain conditions.